Urology Practice Management - June 2021, Vol 7, No 1

The COVID-19 pandemic caused significant disruptions to virtually all aspects of oncology care. There has been a steep drop in cancer diagnoses and screenings—a result of shelter-in-place policies instituted early on, as well as ongoing patient fears about returning to healthcare facilities for new appointments or follow-up care. Read More ›

Cabazitaxel (Jevtana) is approved as third-line therapy for patients with metastatic castration-resistant prostate cancer (CRPC) after treatment with docetaxel and an androgen receptor inhibitor. Read More ›

Cancer does not discriminate based on social status, race, income, or education, but that does not mean that it is an equal-opportunity killer. Evidence shows that overall, patients with poorer socioeconomic status also have poorer health outcomes compared with those with good socioeconomic status. Read More ›

On April 12, 2021, a select group of healthcare professionals involved in the care of patients with urothelial carcinoma (UC) participated in a virtual multidisciplinary panel to discuss best practices in the use of Jelmyto® (mitomycin) for pyelocalyceal solution, which was approved by the US Food and Drug Administration (FDA) in April 2020 for the treatment of adult patients with low-grade upper tract urothelial carcinoma (LG-UTUC). Read More ›

The landscape of cancer and immunology has gone through major scientific advances in research over the past 2 decades. The emergence of immunotherapy as a treatment option for patients diagnosed with cancer has led to improvements in patient outcomes. Read More ›

In patients with metastatic urothelial cancer who received previous therapy, as well as in cisplatin-ineligible patients with this cancer, enfortumab vedotin-ejfv (Padcev) improved overall survival (OS), according to new data presented at the 2021 ASCO Genitourinary Cancers Symposium. Read More ›

The following clinical trials represent a selection of key studies currently recruiting patients with urothelial cancer for inclusion in investigations of new therapies and new regimens of existing treatments for the disease. Read More ›

On April 13, 2021, the FDA accelerated the approval of sacituzumab govitecan (Trodelvy; Immunomedics), a Trop-2 antibody and topoisomerase inhibitor, for patients with locally advanced or metastatic urothelial cancer who had received a platinum-containing chemotherapy and either a PD-1 or a PD-L1 inhibitor. The FDA had granted sacituzumab govitecan a breakthrough therapy designation for this indication. Read More ›